Loading…
Dr. Agarwal's Health Care (AGARWALEYE)₹537.30+4.41%Hospital
In the Jun 2026 quarter (consolidated), Dr. Agarwal's Health Care reported sales of ₹613 Cr, up 26.1% from Jun 2025, and net profit of ₹54.97 Cr, up 44.8% year on year. For the year to Mar 2026, sales were ₹2,077 Cr and net profit ₹168 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 333 | 348 | 402 | 416 | 430 | 459 | 486 | 498 | 529 | 563 | 613 |
| Expenses | 245 | 242 | 301 | 311 | 317 | 330 | 361 | 364 | 388 | 405 | 446 |
| Operating Profit | 88.59 | 108 | 104 | 107 | 115 | 131 | 128 | 135 | 143 | 160 | 169 |
| OPM % | 27.0% | 31.0% | 26.0% | 26.0% | 27.0% | 28.0% | 26.0% | 27.0% | 27.0% | 29.0% | 28.0% |
| Other Income | 12.01 | 20.02 | 6.01 | 11.99 | 12.99 | 13.01 | 13.01 | 7.99 | 10.99 | 13.99 | 6.01 |
| Interest | 21.93 | 26.92 | 26.92 | 27.90 | 27.91 | 24.92 | 24.90 | 22.91 | 20.94 | 21.94 | 22.93 |
| Depreciation | 42.86 | 46.88 | 55.85 | 56.80 | 57.81 | 59.83 | 62.81 | 67.74 | 68.81 | 76.76 | 77.74 |
| Profit before tax | 36.09 | 54.18 | 27.08 | 33.07 | 41.09 | 59.18 | 54.18 | 54.16 | 65.17 | 77.20 | 75.16 |
| Tax % | 37.0% | 24.0% | 33.0% | 36.0% | 31.0% | 27.0% | 29.0% | 32.0% | 33.0% | 35.0% | 27.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −2.01 | 0.00 | 0.00 | 0.00 | 1.01 | 0.00 |
| Net Profit | 22.96 | 40.94 | 17.97 | 20.98 | 27.95 | 42.91 | 37.95 | 35.96 | 43.93 | 49.93 | 54.97 |
| EPS (Rs) | — | — | — | — | 0.71 | 1.02 | 0.94 | 0.93 | 1.06 | 1.24 | 1.42 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 530 | 470 | 695 | 1,016 | 1,330 | 1,708 | 2,077 | 2,204 |
| Expenses | 408 | 388 | 512 | 746 | 969 | 1,252 | 1,517 | 1,602 |
| Operating Profit | 123 | 84.70 | 185 | 274 | 365 | 461 | 568 | 609 |
| OPM % | 23.1% | 18.0% | 27.1% | 27.0% | 28.0% | 27.0% | 27.0% | 27.6% |
| Other Income | 13.01 | 5.99 | 17.01 | 14.01 | 44.04 | 43.04 | 45.98 | 38.98 |
| Interest | 53.86 | 43.82 | 48.86 | 75.78 | 101 | 115 | 89.77 | 88.72 |
| Depreciation | 92.67 | 94.74 | 97.63 | 128 | 170 | 230 | 275 | 291 |
| Profit before tax | −11.02 | −48.10 | 57.18 | 84.19 | 141 | 160 | 250 | 272 |
| Tax % | 82.0% | 21.0% | 24.0% | −24.0% | 32.0% | 31.0% | 32.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 4.01 | 17.04 | 9.03 | 1.01 | 1.01 |
| Net Profit | −20.97 | −58.97 | 42.92 | 103 | 94.87 | 110 | 168 | 185 |
| EPS (Rs) | — | — | — | — | — | 2.63 | 4.18 | 4.65 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 7.03 | 7.03 | 7.03 | 8.04 | 9.02 | 32.12 | 32.15 |
| Reserves | 242 | 177 | 206 | 623 | 1,331 | 1,839 | 1,997 |
| Borrowings | 162 | 185 | 631 | 856 | 964 | 959 | 1,064 |
| Other Liabilities | 339 | 416 | 180 | 335 | 443 | 833 | 847 |
| Total Liabilities | 751 | 786 | 1,024 | 1,822 | 2,748 | 3,663 | 3,940 |
| Fixed Assets | 551 | 575 | 702 | 1,294 | 1,745 | 2,525 | 2,880 |
| CWIP | 7.97 | 10.97 | 27.91 | 98.72 | 118 | 153 | 233 |
| Investments | 0.99 | 0.00 | 0.00 | 33.97 | 470 | 264 | 152 |
| Other Assets | 191 | 200 | 294 | 396 | 414 | 721 | 673 |
| Inventories | 33.12 | 28.09 | 33.10 | 36.12 | 52.21 | 80.33 | 94.25 |
| Trade receivables | 52.17 | 47.15 | 57.13 | 76.19 | 97.25 | 124 | 161 |
| Cash & equivalents | 44.05 | 65.07 | 117 | 149 | 125 | 258 | 129 |
| Total Assets | 751 | 786 | 1,024 | 1,822 | 2,748 | 3,663 | 3,940 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | 103 | 99.36 | 165 | 234 | 347 | 361 | 521 |
| Cash from investing activity | −84.90 | −45.96 | −155 | −509 | −913 | −749 | −308 |
| Cash from financing activity | −72.90 | −36.92 | 34.91 | 302 | 552 | 381 | −220 |
| Net cash flow | −56.13 | 17.04 | 44.09 | 27.06 | −15.03 | −8.02 | −10.01 |
| Capex | 203 | 127 | 71.22 | 159 | 233 | 322 | 463 |
| Free cash flow | −98.44 | 66.24 | 95.35 | 76.31 | 118 | 40.13 | 59.19 |
| CFO / OP % | 97.0% | 126.1% | 97.1% | 98.0% | 103.0% | 86.0% | 101.0% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 37 | 37 | 31 | 28 | 28 | 27 | 29 |
| Inventory days | 179 | 170 | 145 | 117 | 139 | 182 | 179 |
| Days payable | 341 | 453 | 390 | 327 | 356 | 346 | 284 |
| Cash conversion cycle | −126 | −247 | −215 | −183 | −190 | −138 | −76 |
| Working capital days | −31 | −47 | −50 | −62 | −65 | −44 | −3 |
| ROCE % | — | −1.0% | 17.0% | 13.0% | 11.0% | 10.0% | 11.0% |
For the Jun 2026 quarter, Dr. Agarwal's Health Care reported sales of ₹613 Cr, up 26.1% year on year and net profit of ₹54.97 Cr, up 44.8% year on year. The operating margin was 28.0%.
Dr. Agarwal's Health Care's sales for the year to Mar 2026 were ₹2,077 Cr; over the last twelve months they were ₹2,204 Cr.
Net profit for the year to Mar 2026 was ₹168 Cr, and ₹185 Cr over the last twelve months. Earnings per share over the same trailing period were ₹4.65.
Dr. Agarwal's Health Care reported borrowings of ₹1,064 Cr at Mar 2026, against cash and equivalents of ₹129 Cr.
Cash from operations was ₹521 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹59.19 Cr.